AOD-9604 — Vendor Pricing & Purity Guide
Research Overview
AOD-9604 (Anti-Obesity Drug 9604) is a modified fragment of human growth hormone, consisting of the last 16 amino acids of the GH molecule (amino acids 177-191) plus a tyrosine residue. It was developed by Monash University in Australia based on the observation that GH's fat-burning (lipolytic) activity resides in its C-terminal region, while the growth-promoting and diabetogenic effects are in other domains.
The peptide mimics GH's ability to stimulate lipolysis (fat breakdown) and inhibit lipogenesis (fat formation) without the adverse effects associated with full GH administration — specifically, AOD-9604 does not affect IGF-1 levels, blood glucose, or insulin sensitivity. This selectivity for fat metabolism without broader anabolic or metabolic effects made it an attractive anti-obesity candidate.
AOD-9604 completed Phase IIb clinical trials for obesity but was ultimately not approved due to insufficient efficacy at the doses tested. Despite this, it has found commercial success as a TGA-approved ingredient in Australia for osteoarthritis treatment under the brand name "MVT-602" and remains a popular research peptide for body composition studies.
Key Research Findings
- •Stimulated lipolysis in fat cells at rates comparable to full-length growth hormone without affecting IGF-1 or insulin
- •Inhibited both lipogenesis (fat creation) and lipolysis (fat breakdown), favoring net fat reduction in obese rodent models
- •Phase IIb clinical trial showed modest but statistically significant weight loss over 12 weeks in obese subjects
- •No effect on blood glucose or HbA1c — confirming separation of lipolytic from diabetogenic GH effects
- •TGA-approved in Australia for intra-articular injection in osteoarthritis treatment
- •Demonstrated cartilage-protective and regenerative properties in joint research models
Research Dosage Protocols
AOD-9604 is supplied as lyophilized powder reconstituted with bacteriostatic water. It has been studied via subcutaneous injection and oral administration.
In the Phase IIb obesity trial, oral doses of 1 mg daily were used. Subcutaneous research protocols have used 300-500 mcg daily. The peptide has also been studied via intra-articular injection at higher doses for osteoarthritis applications.
AOD-9604 is often researched alongside other metabolic peptides such as 5-Amino-1MQ and Semaglutide, though their mechanisms differ significantly. AOD-9604 specifically targets GH receptor-mediated lipolysis.
For research reference only. Not medical advice. Not for human consumption.
Published Research (1 studies)
- [1]A fragment of human growth hormone (AOD9604) with improved lipolytic activity— Heffernan et al., 2001PMID: 11713213
Links go to PubMed (NIH National Library of Medicine). PeptideVerdict is not affiliated with these studies.
Price Comparison (14 products from 12 vendors)
| Vendor | Price | Stock |
|---|---|---|
| Particle Peptides | $37.99 $7.60/mg 5mg lyophilized | In Stock |
| Paradigm Peptides | $39.99 $8.00/mg 5mg lyophilized | In Stock |
| Peptide Crafters | $80.00 $8.00/mg 10mg topical | In Stock |
| Core Peptides | $41.00 $8.20/mg 5mg vial | In Stock |
| Biotech Peptides | $44.00 $8.80/mg 5mg vial | In Stock |
| Simple Peptide | $45.00 $9.00/mg 5mg lyophilized | In Stock |
| Peptide Crafters | $45.00 $9.00/mg 5mg topical | In Stock |
| Astro Peptides | $45.00 $9.00/mg 5mg lyophilized | In Stock |
| Peptide Sciences | $65.00 $10.83/mg 6mg lyophilized | In Stock |
| Soma Chems | $59.99 $12.00/mg 5mg vial | In Stock |
| Polaris Peptides | $40.00 $20.00/mg 2mg lyophilized | In Stock |
| Limitless Biotech | $9604.00 lyophilized | Out |
| Soma Chems | $79.99 spray | In Stock |
| Skye Peptides | $69.00 lyophilized | In Stock |
Frequently Asked Questions
What is AOD-9604?
AOD-9604 is a modified fragment of growth hormone (amino acids 177-191) that retains GH's fat-burning effects without affecting growth, blood sugar, or IGF-1 levels. It was developed as an anti-obesity drug.
Does AOD-9604 work for weight loss?
AOD-9604 demonstrated lipolytic activity in preclinical studies and modest weight loss in a Phase IIb human trial. It was not FDA-approved due to insufficient efficacy at tested doses. It has been TGA-approved in Australia for osteoarthritis.
How does AOD-9604 compare to Semaglutide for fat loss?
They work through completely different mechanisms. Semaglutide suppresses appetite via GLP-1 receptors in the brain. AOD-9604 directly stimulates fat cell lipolysis via a GH receptor fragment. Semaglutide has dramatically stronger clinical efficacy data.
Where can I buy AOD-9604 for research?
AOD-9604 is available from research peptide vendors. Compare pricing in the table above.